Search results
Health care 'price fixing' has gone high tech, but the FTC chief is on the case
BenefitsPRO· 4 days agoConsolidation in health care has evolved and hiring people who can "help us look under the hood" of...
TikTok’s Push for Users to Lobby Congress Should Be Investigated, Lawmakers Say
The Wall Street Journal· 1 day agoExhortations to users to contact their representatives amid a debate over banning the app might have...
FTC Non-Compete Ban Could Impact Wirehouses and Banks More Than RIAs
WealthManagement.com· 3 days agoThe FTC voted 3-2 last week to adopt a comprehensive ban on non-compete provisions that would stop...
Williams-Sonoma to pay $3.2M for violating FTC’s Made in USA order
Retail Dive via Yahoo Finance· 3 days ago“Williams-Sonoma’s deception misled consumers and harmed honest American businesses,” FTC Chair Lina...
FTC Targets ‘Junk’ Patent Listings on Ozempic and Other Drugs
The Wall Street Journal· 3 days ago“By filing bogus patent listings, pharma companies block competition and inflate the cost of...
US challenges ‘bogus’ patents on Ozempic and other drugs in effort to spur competition
FOX 16 Little Rock· 4 days agoWASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration target…
‘Smartphones on Wheels’ Draw Attention From Regulators
New York Times· 4 days agoModern cars are internet-connected and have hundreds of sensors. Lawmakers and regulators have...
ExxonMobil’s $60bn Pioneer acquisition nears FTC approval
Offshore Technology via Yahoo Finance· 2 days agoThe US Federal Trade Commission's (FTC) nod is expected following an agreement that Pioneer's...
Here’s How the News Networks are Celebrating AANHPI Heritage Month
AdWeek· 14 hours agoLook for multiple special reports and programs shining a spotlight on leading AANHPI figures across...
FTC targets ‘junk patents’ on Ozempic, other top drugs
BioPharma Dive via Yahoo Finance· 3 days agoThe move broadens the antitrust regulator’s campaign against allegedly “improper or inaccurate”...